Frequency of different clinical presentations/ symptoms of irritable bowel syndrome in patients presenting to the outpatient department of lady reading hospital Peshawar

Kamran Kamran; Muhammad Sohail; Muhammad Fahim; Muhammad Sajjad Khan; Syeddah Rubina Gillani; Ruqayya Rehman; Noman Khan; Umair Alam

doi:10.53730/ijhs.v6nS10.13902

Authors

Kamran Consultant Gastroenterologist, Primary Health Services, Charsadda Pakistan
Muhammad Sohail Consultant Gastroenterologist, Primary Health Services, Mardan Pakistan
Muhammad Fahim Consultant Gastroenterologist, MTI Mardan Medical Complex, Mardan Pakistan
Muhammad Sajjad Khan
dr_waziri2011@yahoo.com
Medical Office, Primary Health Services, Bannu Pakistan
Syeddah Rubina Gillani Medical Officer, Primary Health Services, Nowshehra Pakistan
Ruqayya Rehman Medical Officer, Primary Health Services, Charsadda Pakistan
Noman Khan Medical Officer Primary Health Services, Peshawar Pakistan
Umair Alam Medical Officer, Khyber Teaching Hospital, Peshawar Pakistan

Keywords:

clinical presentations, frequent stools, looser stools, infrequent stools, harder stools, abdominal pain

Abstract

In the absence of any structural aetiology, irritable bowel syndrome is a condition of gastrointestinal motility and sensation that is defined by persistent abdominal pain and irregular bowel movements. It is the communal reasons for gastroenterology consultations. Therefore, knowledge of the relative frequency of these symptoms in our population will enable healthcare practitioners to tailor their management to the symptom patterns of our population. Objective: To determine the frequency of different clinical presentations/symptoms (frequent stools, looser stools, infrequent stools, harder stools, abdominal pain) of irritable bowel syndrome in patients presenting to the outpatient department of Lady Reading Hospital, Peshawar. Place and Duration: In Gastroenterology outpatient department of Lady Reading Hospital, Peshawar for six months duration from 25^th June, 2019 to 25^th December, 2019. Study Design: A Cross-sectional Study. Methods: In this study a total 192 patients were observed. The patients were given a questionnaire containing questions about their clinical presentation including present and past symptoms. These questions were including details of how frequently they need to pass stools, consistency/form of stools (graded according to Bristol Stool Chart) as well as presence or absence of pain.

Downloads

Download data is not yet available.

References

American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(11 suppl):S1–5.

Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment PharmacolTher. 2009;20(Suppl 2):1–9.

Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease?. Gastroenterol Clin North Am. Jun 2005;34(2):235-45.

Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71.

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949-58.

Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651-60.

Ghoshal UC, Abraham P, Bhatt C. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol. 2008;27:22-8.

Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Frequency ofirritable bowel syndrome in college students.J Ayub Med Coll. 2005;17(4):9–11.

Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Irritable bowel syndrome and health seeking behavior in different communities of Pakistan. J Pak Med Assoc.2007;57(6):285–7.

Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. ClinExpGastroenterol. 2011;4:43–8.

Krogius-Kurikka L, Lyra A, Malinen E. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol. 2009;9:95.

Majewski M, Reddymasu S, Sostarich S, Foran P, McCallum R. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. AmJ Med Sci.2007;333:266–70.

Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ. 1978;2(6138):653-4

Olden KW. Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Cleve Clin J Med. 2003;70(suppl 2):S3–7.

Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Sub analysis of a double-blind randomized controlled study. Dig Dis Sci. 2010; 51(8):1297–301.

Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2010;95(12):3503–6.

Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2008;98(2):412–9.

Pimentel M., Lembo A., Chey W., Zakko S., Ringel Y., Yu J., et al. TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation. NEngl J Med. 2011;364:22–32.

Schoepfer A. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment PharmacolTher.2012;36(11):1084–93.

Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for colorectal disorders: implications for clinical practice. Curr Gastroenterol Rep. 2017;19(4):15

Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. Apr 2010;105(4):848-58.

Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. NeurogastroenterolMotil. 2010;22(5):512–9.

Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:43–7.

Wong RK, Drossman DA, Weinland SR, Morris CB, Leserman J, Hu Y, et al. Partner burden in irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2013;11(2):151-5..

Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53(1):169–74.